Careers  |  Sign In  |  Register

CARMENA Trial: Should Nephrectomy Be Standard for Metastatic RCC?


Results from the CARMENA trial, presented at the 2019 annual meeting of the American Society of Clinical Oncology suggest that cytoreductive nephrectomy should no longer be considered the standard care for metastatic renal cell carcinoma (RCC). With the exception of one subgroup of patients, nephrectomy plus sunitinib was not superior to sunitinib alone in the majority of patients.

Learn more by clicking here.